Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Adopts Stimulus Package, Set to Support Domestic API Production
October 31, 2022
- Think Tanks Propose New Pricing Methods for Innovative Meds, Multi-Faceted Evaluations
October 28, 2022
- Policy Veterans’ Group Advocates Drug Reimbursement at Actual Purchase Prices
October 28, 2022
- Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
October 28, 2022
- Chuikyo to Discuss 2023 Off-Year Re-Pricing with Its Implementation as Premise: MHLW
October 27, 2022
- LDP to Launch Lawmakers’ League on Medical Adhesive Patches
October 27, 2022
- Bill to Amend Infectious Disease Act and Other Laws Enter Diet Deliberations
October 26, 2022
- Pfizer Assesses Cancer Risk from Amoxan as “Acceptable” at “1 in 200,000 People”
October 26, 2022
- New Economic Package to Drive Antibiotic API Production, Vaccine Trials in Japan
October 25, 2022
- Commodity Prices Are Rising, That’s Why Full Drug Re-Pricing Needed in 2023: MOF Official
October 25, 2022
- Moderna’s BA.4/5 COVID Jab Up for PAFSC Review on Oct. 31
October 25, 2022
- Early Approval, Reimbursement of SaMD Put on Priority Agenda: Deregulation Panel
October 25, 2022
- Japan Might Change Timing of Drug Price Revisions from April amid Medical DX Push
October 24, 2022
- Nearly 700 Key Drugs Found to Be Unprofitable Due to Inflation, FX: Survey
October 24, 2022
- Is New Expert Panel All about Drug Pricing System? Asks Chair
October 24, 2022
- Experts Call for Debate on Scope of Health Coverage, “Exit Rule” for Unnecessary Meds
October 24, 2022
- PMDA Reviewing New Safety Risks for Evrenzo and More Drugs
October 24, 2022
- With Shortened Interval, Omicron Booster Likely to Cover 18 Million More People by Month-End
October 21, 2022
- LDP Project Team to Present Proposal for FY2023 Drug Price Revision and Budget Planning
October 21, 2022
- COVID Booster Interval to Be Shortened to “At Least 3 Months”
October 20, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…